Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCH | P24723 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8711978 | 0.79 | — | — | |
| SCHEMBL31680277 | 0.79 | — | — | |
| SCHEMBL13218969 | 0.79 | MAPT (0.33) | PRKCGPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL15906687 | 0.77 | L3MBTL1 (0.32) | MAPT | |
| SCHEMBL20548386 | 0.76 | MAPT (0.31) | MAPT | |
| SCHEMBL6580747 | 0.73 | GAA (0.50) | MAPTPABPC1CTDSP1GAA | |
| SCHEMBL6218416 | 0.73 | GAA (0.50) | MAPTPABPC1CTDSP1GAA | |
| SCHEMBL16161530 | 0.73 | PABPC1 (0.32) | PABPC1CTDSP1 | |
| SCHEMBL8192982 | 0.71 | PABPC1 (0.53) | PABPC1CTDSP1GAA | |
| SCHEMBL1487109 | 0.71 | PABPC1 (0.53) | PABPC1CTDSP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151580-A1 | Synthetic spiroketal pyranes as potent anti-cancer agents and use | PARKER HUGHES INSTITUTE (US) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151580-A1 | Synthetic spiroketal pyranes as potent anti-cancer agents and use | TUBB6, TUBAL3, TUBB1 | PRKCG 3276/4885PRKCB 3256/4885PRKCA 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.